Impact of Vitamin D Injection on Keloids and Hypertrophic Scars.
Study Goal
To study the effect of intralesional and systemic Vitamin D3 injection on hypertrophic scars and keloids and whether vitamin D3 deficiency increases scarring.
Results Summary
Vitamin D deficiency did not affect scar formation or severity. Both groups showed significant improvement in vascularity and pliability but no change in scar pigmentation or height. No significant difference was found between groups post-intervention.
Population
30 patients with hypertrophic scars and keloids, divided by serum vitamin D levels.
Effective Dosage
Systemic injection of cholecalciferol 200,000 I.U. once monthly for 3 months (Group I); intralesional vitamin D injections (both groups).
Duration
3 months
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Vitamin D | decrease | keloid fibroblast proliferation | - | - | inhibits | #1 |
Vitamin D | decrease | TGF-β-induced extracellular matrix formation | - | - | reducing | #2 |
Vitamin D | increase | matrix metalloproteinase activity | - | - | boosting | #3 |
Vitamin D | decrease | inflammation | - | - | reducing | #4 |
Vitamin D deficiency | no change | scar formation or severity | hypertrophic scars and keloid patients | p value > 0.05 | did not affect | #5 |
intralesional and systemic Vitamin D3 injection | decrease | vascularity | hypertrophic scars and keloid patients | p value < 0.05 | substantial drop | #6 |
intralesional and systemic Vitamin D3 injection | decrease | pliability | hypertrophic scars and keloid patients | p value < 0.05 | substantial drop | #7 |
intralesional and systemic Vitamin D3 injection | decrease | total Vancouver scale score | hypertrophic scars and keloid patients | p value < 0.05 | substantial drop | #8 |
intralesional and systemic Vitamin D3 injection | no change | scar pigmentation | hypertrophic scars and keloid patients | - | no change | #9 |
intralesional and systemic Vitamin D3 injection | no change | scar height | hypertrophic scars and keloid patients | - | no change | #10 |
intralesional and systemic Vitamin D3 injection | no change | scar assessment | research groups | p > 0.05 | did not significantly differ | #11 |
Injection of vitamin on hypertrophic scars and keloids | increase | vascularity | patients with sufficient serum vitamin D levels | - | enhances | #12 |
Injection of vitamin on hypertrophic scars and keloids | increase | pliability | patients with sufficient serum vitamin D levels | - | enhances | #13 |
Injection of vitamin on hypertrophic scars and keloids | increase | vascularity | patients with deficient or insufficient serum vitamin D levels after improving them by systemic injection of vitamin D | - | enhances | #14 |
Injection of vitamin on hypertrophic scars and keloids | increase | pliability | patients with deficient or insufficient serum vitamin D levels after improving them by systemic injection of vitamin D | - | enhances | #15 |
Injection of vitamin on hypertrophic scars and keloids | no change | height of scars | - | - | without any effect | #16 |
Injection of vitamin on hypertrophic scars and keloids | no change | pigmentation of scars | - | - | without any effect | #17 |
BACKGROUND: Hypertrophic scars and keloids are human cutaneous fibroproliferative conditions that develop after burns, trauma, surgery, and inflammation. Vitamin D inhibits keloid fibroblast proliferation by reducing TGF-β-induced extracellular matrix formation, boosting matrix metalloproteinase activity, and reducing inflammation. AIM: To study the effect of intralesional and systemic Vitamin D3 injection on hypertrophic scars and keloids and whether vitamin D3 deficiency increases scarring. PATIENTS AND METHODS: This study included 30 hypertrophic scars and keloid patients divided into groups depending on serum vitamin D levels. Every patient was tested for vitamin D using ELISA. Group I: patients with vitamin D deficiency or insufficiency received a systemic injection of vitamin D (cholecalciferol 200 000 I.U.) once monthly for 3 months with a calcium oral supplement and intralesional vitamin D injections on hypertrophic scars and keloids. Group II: patients with sufficient vitamin D received only intralesional vitamin D injections. RESULTS: Vitamin D deficiency did not affect scar formation or severity (total Vancouver scar scale before assessment) with a p value > 0.05. All instances showed a substantial drop in vascularity, pliability, and total Vancouver scale score (p value < 0.05) following intervention, but no change in scar pigmentation or height. Scar assessment following intervention did not significantly differ between research groups (p > 0.05). CONCLUSION: Injection of vitamin on hypertrophic scars and keloids enhances vascularity and pliability in patients with sufficient serum vitamin D levels and those with deficient or insufficient serum vitamin D levels after improving them by systemic injection of vitamin D without any effect on height and pigmentation of scars. TRIAL REGISTRATION: NCT06301178.